Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
about
Imaging of prehospital stroke therapeuticsThe Yin and Yang of innate immunity in strokeHealth promotion interventions for increasing stroke awareness in ethnic minorities: a systematic review of the literatureThe immunology of stroke: from mechanisms to translationTime to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trialHeart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationCurrent perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokePrehospital utility of rapid stroke evaluation using in-ambulance telemedicine: a pilot feasibility studyReview of stroke center effectiveness and other get with the guidelines data.[Stroke: How can "time is brain" be translated into clinical practice?].Intravenous Tissue Plasminogen Activator Can Be Safely Given without Complete Blood Count Results Back.New standardized nursing cooperation workflow to reduce stroke thrombolysis delays in patients with acute ischemic stroke.TREM2 protects against cerebral ischemia/reperfusion injuryUtilization of emergency medical service increases chance of thrombolytic therapy in patients with acute ischemic stroke.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Evaluation of the implementation of a rapid response treatment protocol for patients with acute onset stroke: can we increase the number of patients treated and shorten the time needed?Stroke code improves intravenous thrombolysis administration in acute ischemic strokeEvaluation of interval times from onset to reperfusion in patients undergoing endovascular therapy in the Interventional Management of Stroke III trialStroke research at a crossroad: asking the brain for directionsA cluster randomized trial to assess the effect of clinical pathways for patients with stroke: results of the clinical pathways for effective and appropriate care study.Blood pressure management in stroke: Five new things.Process improvement to enhance existing stroke team activity toward more timely thrombolytic treatmentPrehospital stroke care: new prospects for treatment and clinical researchFunctional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain.Secretomes of apoptotic mononuclear cells ameliorate neurological damage in rats with focal ischemia.Outcome determinants of stroke in a brazilian primary stroke center.The role of microglia and myeloid immune cells in acute cerebral ischemia.Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentialsDifferences in process management and in-hospital delays in treatment with iv thrombolysisRecombinant tissue plasminogen activator for the treatment of acute ischemic stroke.Spatial distribution of insulin-like growth factor binding protein-2 following hypoxic-ischemic injuryGeographic and sociodemographic disparities in drive times to Joint Commission-certified primary stroke centers in North Carolina, South Carolina, and Georgia.Contemporary trends and predictors of postacute service use and routine discharge home after stroke.In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.Problems and limitations in thrombolysis of acute stroke patients at a tertiary care center.Organization of a United States county system for comprehensive acute stroke care.Short Door-to-Needle Times in Acute Ischemic Stroke and Prospective Identification of Its Delaying Factors.Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.Increase in national intravenous thrombolysis rates for ischaemic stroke between 2005 and 2012: is bigger better?Generalization of the Right Acute Stroke Prevention Strategies in Reducing in-Hospital Delays.
P2860
Q26797275-05AEAE0F-9407-4855-9BEF-CCC795954DDBQ26822268-E6F99727-15B8-49FC-A6C4-48EA18A2D163Q27003376-833DB100-A573-4F00-9B67-48F1551D0B14Q29620066-8BD43929-8892-4639-8AF3-96A40B71C03EQ30000128-3789F958-5612-464B-93F9-F9DF47804E77Q30238784-FA45FAF5-0A5A-4C1D-A746-832D324CB8B0Q30414441-146116B8-254C-44CD-9BCC-0EADAE976DE9Q30585416-E1C29C27-E0AD-4CE9-A7CE-88329668374AQ30657743-032660A2-4264-4E5E-A756-BA8C2DD78BCEQ31034917-5B040513-EBD6-4B07-84AB-D396813EBDB5Q33424165-1D394723-4E27-4968-9672-589A10259E8DQ33686589-F1F5380A-1A75-4187-B029-3F776334AFD9Q33771678-C3564E90-970C-4092-B19F-FEB58CE9226CQ33801117-1B0B056E-8826-43F3-9F10-2BF45FF56B67Q33863833-29EE9A58-27F6-4531-94F6-E4A2AC51CE45Q33886756-1DF94615-A4F9-40DC-AB25-8481B157EE77Q34027950-FAC629BA-AD4A-4018-94C9-978111BCF8ECQ34028589-89786BD4-0B73-4CB7-AE39-4DD2E7B751F6Q34227730-CC961C84-C62D-4DCE-AEBE-C667DF706E0CQ34332427-59341589-AC44-4E93-8BBC-3CFADD2A500CQ34335858-DD144162-1A42-4239-B201-04AD86C73415Q34346571-86932BAE-47E8-4EFB-B352-068B93B22B82Q34360614-3630FBB3-9EB7-4D9C-AF18-FD3A61653A59Q34380550-A8D747BB-CA3E-4641-BD1E-622403CF8FCFQ34433639-0110D20A-4220-4E84-8FF1-9A1530265131Q34785716-7786CB98-A208-44E8-864E-BBBC5102E476Q34954361-80EBCBE2-016D-4064-A9BC-AC7F9D6E29A7Q34972793-B1A05169-36A4-4706-87EA-F14EFFCDE496Q34999568-E12B2474-881B-45E3-80C0-216BD811E94DQ35073100-3AD74726-8916-44FA-B79C-E3AB95E8322AQ35073816-F31AB08B-10E7-4B89-A025-4969FDE95AD2Q35107159-82AE9BF7-614E-4C5F-90FF-9317736F1C1DQ35135652-F11E284C-E23E-42F4-935C-7F4CAA8B4572Q35563036-BEB81750-8493-49F1-A189-88F9C1273585Q35603744-4FC01A96-5A9D-4F7F-A10F-1C2C7E11E418Q35858774-61224BCD-8CC5-43D4-833D-2D825B3747ACQ35901675-F523E9D6-5591-418B-8EBD-1FE5AC603E9DQ35992243-0A1D9A4E-338F-4622-B2D6-F5F9F4CA0511Q35996684-9A60F09A-0F78-4A13-98B8-BF0E163B380CQ36010802-E52B3D00-2C73-4420-894E-2032CCBAD30C
P2860
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@en
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@nl
type
label
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@en
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@nl
prefLabel
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@en
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@nl
P2093
P50
P1433
P1476
Timeliness of tissue-type plas ...... eedle times within 60 minutes.
@en
P2093
DaiWai M Olson
Deepak L Bhatt
Maria V Grau-Sepulveda
Mathew J Reeves
P304
P356
10.1161/CIRCULATIONAHA.110.974675
P407
P577
2011-02-10T00:00:00Z